Sellas Life Sciences is trading at $14.75, up 10.07%, as investors anticipate the approaching REGAL trial readout.
- No new company-specific announcement was identified on August 21, 2026; the latest official update said final analysis follows the trial’s 80th event.
- Biotech momentum provided additional support, with XBI up 2.02% during regular trading.
- The move appears driven by active trading and anticipation rather than a newly disclosed catalyst.